本文選題：增強型體外反搏 + 麝香保心丸�。� 參考：《廣州中醫(yī)藥大學(xué)》2015年碩士論文

【摘要】：目的：通過觀察生長分化因子(Growth Differentiation-Factor-15, GDF-15)、白細(xì)胞介素6 (Interleukin 6,IL-6)、超敏C反應(yīng)蛋白(High Sensitivity C-Reactive Protein, hs-CRP)三個炎癥因子的變化,結(jié)合中醫(yī)療效判定,初步評估增強型體外反搏(Enhanced External Counterpulsation, EECP)聯(lián)合麝香保心丸(Shexiang Baoxin Pill, SXBX)治療對氣虛血瘀型急性心肌梗死(Acute Myocardial Infarction, AMI)患者經(jīng)皮冠脈介入治療(Percutaneous Coronary Intervention, PCI)術(shù)后效果的意義。方法：本研究采用病例-對照及自身對照研究的設(shè)計方法,選取行PCI術(shù)的氣虛血瘀型AMI患者60例,隨機分為兩組：對照組和EECP+SXBX組,每組各30例。對照組常規(guī)西藥治療,EECP+SXBX組在常規(guī)西藥基礎(chǔ)上加用EECP和麝香保心丸,7天為一個療程。分別檢測術(shù)前15分鐘、術(shù)后第3天、術(shù)后第7天不同時間點的GDF-15、IL-6、hs-CRP的濃度,記錄術(shù)前和術(shù)后第7天的臨床癥候。結(jié)果：EECP+SXBX組和對照組治療前血清hs-CRP、IL-6、GDF-15濃度差異無統(tǒng)計學(xué)意義(P0.05)；治療后,兩組病例術(shù)后第3天血清hs-CRP、IL-6、GDF-15濃度均比術(shù)前升高,差異具有統(tǒng)計學(xué)意義(均P0.05)；EECP+SXBX組術(shù)后第3天血清hs-CRP、 IL-6、GDF-15濃度升高幅度比對照組低,兩組術(shù)后第3天與術(shù)前差值比較,差異有統(tǒng)計學(xué)意義(P0.05); EECP+SXBX組術(shù)后第7天血清hs-CRP、IL-6、GDF-15濃度下降幅度比對照組高,兩組術(shù)后第7天與術(shù)前差值比較,差異有統(tǒng)計學(xué)意義(P0.05)；EECP+SXBX組顯效7例,有效19例,無效3例,加重1例；對照組顯效2例,有效12例,無效13例,加重3例兩組比較,差異有統(tǒng)計學(xué)意義(P0.05)。結(jié)論：PCI術(shù)可引起血管內(nèi)皮損傷和炎癥反應(yīng)；EECP聯(lián)合麝香保心丸治療可以減輕PCI術(shù)后血管內(nèi)皮損傷和炎癥反應(yīng)；EECP聯(lián)合麝香保心丸治療可改善心肌微循環(huán),促進心肌修復(fù)和心臟康復(fù)。
[Abstract]:Objective: to observe the changes of growth differentiation factor (Growth differentiation) Factor-15 (GDF-15), interleukin 6 (IL-6) and high Sensitivity C-Reactive protein (hs-CRP) in order to determine the efficacy of traditional Chinese medicine (TCM). To evaluate the effect of enhanced External Counterpulsation, EECP) combined with Shexiang Baoxin Pill, SXBX) in the treatment of acute myocardial infarction with Qi deficiency and blood stasis after percutaneous coronary intervention (PCI) for patients with acute myocardial infarction (AMI) with Qi deficiency and blood stasis. Methods: in this study, 60 cases of AMI with Qi deficiency and blood stasis were randomly divided into two groups: control group and EECP SXBX group, 30 cases in each group. The control group treated EECP SXBX with routine western medicine plus EECP and Shexiang Baoxin Pill for 7 days as a course of treatment. The levels of GDF-15 IL-6hs-CRP were measured 15 minutes before operation, 3 days after operation and 7 days after operation. The clinical symptoms were recorded before and 7 days after operation. Results there was no significant difference in serum hs-CRPnIL-6GDF-15 concentration between the two groups before treatment, and the serum hs-CRPG-6GDF-15 level was higher in the two groups on the 3rd day after treatment than that before operation, and there was no significant difference between the two groups in serum hs-CRP- IL-6GDF-15 concentration before and after treatment, and there was no significant difference between the two groups before and after treatment. The serum hs-CRP and IL-6 GDF-15 concentrations in the EECP SXBX group were significantly lower than those in the control group on the 3rd day after operation, and the difference between the two groups on the 3rd day after operation was compared with that before operation. There was a significant difference between the two groups on the 7th day after operation, and the decrease of serum hs-CRP- IL-6 GDF-15 concentration in the EECP SXBX group was higher than that in the control group, and the difference between the two groups on the 7th day after operation was statistically significant compared with the preoperative difference. The difference was significant in 7 cases, 19 cases and 3 cases in the EECP SXBX group, and the difference was significant in 7 cases, 19 cases and 3 cases, respectively. In the control group, there were 2 cases with marked effect, 12 cases with effective effect, 13 cases with no effect and 3 cases with aggravation, the difference was statistically significant (P 0.05). ConclusionEECP combined with Shexiang Baoxin Pill can reduce vascular endothelial injury and inflammatory response after PCI, can improve myocardial microcirculation, promote myocardial repair and cardiac rehabilitation.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R541.4

【參考文獻】

相關(guān)期刊論文 前10條

1 鄭凌冰;郭艷紅;于海奕;米琳;汪宇鵬;高煒;;血清生長分化因子-15與急性冠狀動脈綜合征的相關(guān)性分析[J];北京大學(xué)學(xué)報(醫(yī)學(xué)版);2011年02期

2 鄧明堯;吳國平;馮旭霞;羅江賓;;不穩(wěn)定性心絞痛患者血清生長分化因子15與TIMI危險評分的相關(guān)性[J];南方醫(yī)科大學(xué)學(xué)報;2011年07期

3 徐瑋;吳繼雄;王本芳;蔡鑫;;冠心病患者血清生長分化因子15C反應(yīng)蛋白水平與冠狀動脈病變程度的相關(guān)性分析[J];安徽醫(yī)學(xué);2013年04期

4 謝淋;丁世芳;蔣桔泉;陳志楠;盧青;王華;彭毅;;不同時段PCI對STEMI患者血清hs-CRP、IL-6的影響及臨床意義[J];華南國防醫(yī)學(xué)雜志;2012年03期

5 周元風(fēng);胡永兵;洪浪;;麝香保心丸對動脈粥樣硬化兔血脂及hs-CRP的影響[J];實用臨床醫(yī)學(xué);2013年04期

6 聶謙;許勇;;冠心病介入治療后再狹窄機制的中西醫(yī)研究進展[J];世界科學(xué)技術(shù)-中醫(yī)藥現(xiàn)代化;2013年05期

7 羅初凡;杜志民;胡承恒;伍貴富;張苗青;;冠心病介入治療患者體外反搏的療效探討[J];現(xiàn)代臨床醫(yī)學(xué)生物工程學(xué)雜志;2006年03期

8 楊達雅;伍貴富;;體外反搏作用的新機制:提高血流切應(yīng)力與血管內(nèi)皮功能保護[J];心血管病學(xué)進展;2009年05期

9 錢孝賢,鄭振聲,吳偉康,陳燕銘,張書剛,高國全,陸麗;體外反搏對心肌梗死犬一氧化氮系統(tǒng)的影響[J];中國病理生理雜志;2000年11期

10 陳小林;劉婷婷;余澤洪;劉儉;劉伊麗;劉冬紅;馬虹;;增強型體外反搏改善經(jīng)皮冠狀動脈介入治療術(shù)后心肌無再流現(xiàn)象[J];中華高血壓雜志;2008年08期

，

本文編號：1898181